GlassScriptPhysician profile
Saurabh K Sharma
NPI 1629136478
$15,065.39
in general payments reported to CMS, 2019-2025
26 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,627 · 2020: $2,804 · 2021: $2,850 · 2022: $1,520 · 2023: $1,569 · 2024: $1,853 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,247 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,247.10 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,335.37 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $2,229.81 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Novo Nordisk INC | $1,656.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,592.62 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $1,253.23 | 2019-2025 | Evenity, Repatha, Prolia |
| Sanofi-Aventis U.S. LLC | $877.53 | 2019-2022 | |
| Amarin Pharma, INC. | $775.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $621.65 | 2019-2023 | Xarelto |
| Pfizer INC. | $537.98 | 2019-2025 | |
| Esperion Therapeutics, INC. | $478.62 | 2020-2021 | |
| Abbvie INC. | $422.04 | 2021-2023 | Vraylar |
| Lundbeck LLC | $389.64 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $298.86 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $269.20 | 2022 | |
| Glaxosmithkline, LLC. | $237.02 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $224.35 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $220.30 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.94 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $94.61 | 2024 | Rexulti |
| Abbott Laboratories | $85.35 | 2025 | Freestyle Libre 3 |
| Allergan, INC. | $77.75 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $75.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $61.96 | 2019-2021 | |
| Neurent Medical Limited | $39.94 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Takeda Pharmaceuticals U.S.A., INC. | $24.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.